close
Add to watchlist
Prana Biotech Depository Receipt (PRAN) Healthcare, Biotechnology & Drugs
Prana Biotechnology Limited, a development stage company, engages in the research and development of therapeutic drugs in Australia. The company offers PBT-2, a Phase IIa clinical trial product for the treatment of Alzheimer's disease. Its product is designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. The company's product is also applied for other therapies, including age-related cataracts, Huntington disease, Creutzfeldt-Jakob disease, Motor Neuron disease, age-related macular degeneration, cancers, Parkinson's disease, and other neurodegenerative diseases. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 1.71 |
| Volume | 15432 |
| Volume Avg | 94136 |
| 52 Week High | 4.50 |
| 52 Week Low | 1.40 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.23 |
| EPS change Q/Q | 100% |
| EPS change Q/Q Yr ago | -100% |
| EPS change Q/Q next Q est | 100% |
| EPS change Y/Y | 0% |
| REV change Q/Q | -100% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | 0.00 |
| EPS next Y est | -0.26 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |